Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm

A. R. Bentivoglio, A. Fasano, T. Ialongo, F. Soleti, S. Lo Fermo, A. Albanese

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Background and purpose: To review the clinical characteristics and the long-term outcome of patients with hemifacial spasm (HFS) who received botulinum neurotoxin (BoNT) over the past 10 years. Results: A total of 108 patients received 665 treatments. Mean latency of clinical effect was 5.4 ± 5.3 days for Botox and 4.9 ± 4.6 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher after the injection of Dysport than Botox: 105.9 ± 54.2 and 85.4 ± 41.6 days respectively (P <0.01). The percentage of treatment failures was 6.5% for Botox and 4.6% for Dysport (P > 0.05). The doses of Botox significantly increased over time (β = 0.35, P <0. 001) whilst Dysport dose remained unchanged (β = 0.16, n.s.). The duration of clinical benefit slightly increased with Botox (β = 0.12; P <0.01), but remained constant for Dysport. Side effects occurred in 17.4% of treatments: 16.7% of patients who had received Botox, and in 19.7% who had received Dysport (P > 0.05). The most common side effects were palpebral ptosis and lacrimation; ptosis and lagophtalmos was more common in Dysport treatments (P <0.005). Conclusions: Both brands are effective and safe in treating HFS; efficacy is long-lasting. The differences in outcome and side effects confirm that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.

Original languageEnglish
Pages (from-to)392-398
Number of pages7
JournalEuropean Journal of Neurology
Volume16
Issue number3
DOIs
Publication statusPublished - Mar 2009

Fingerprint

Hemifacial Spasm
Safety
Neurotoxins
Eyelids
Therapeutics
Pharmaceutical Preparations
Injections
onabotulinumtoxinA
abobotulinumtoxinA

Keywords

  • Botox
  • Botulinum neurotoxin
  • Dysport
  • Hemifacial spasm
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. / Bentivoglio, A. R.; Fasano, A.; Ialongo, T.; Soleti, F.; Lo Fermo, S.; Albanese, A.

In: European Journal of Neurology, Vol. 16, No. 3, 03.2009, p. 392-398.

Research output: Contribution to journalArticle

Bentivoglio, A. R. ; Fasano, A. ; Ialongo, T. ; Soleti, F. ; Lo Fermo, S. ; Albanese, A. / Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. In: European Journal of Neurology. 2009 ; Vol. 16, No. 3. pp. 392-398.
@article{ac0f1f7121ba496ebb5acc44844bc133,
title = "Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm",
abstract = "Background and purpose: To review the clinical characteristics and the long-term outcome of patients with hemifacial spasm (HFS) who received botulinum neurotoxin (BoNT) over the past 10 years. Results: A total of 108 patients received 665 treatments. Mean latency of clinical effect was 5.4 ± 5.3 days for Botox and 4.9 ± 4.6 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher after the injection of Dysport than Botox: 105.9 ± 54.2 and 85.4 ± 41.6 days respectively (P <0.01). The percentage of treatment failures was 6.5{\%} for Botox and 4.6{\%} for Dysport (P > 0.05). The doses of Botox significantly increased over time (β = 0.35, P <0. 001) whilst Dysport dose remained unchanged (β = 0.16, n.s.). The duration of clinical benefit slightly increased with Botox (β = 0.12; P <0.01), but remained constant for Dysport. Side effects occurred in 17.4{\%} of treatments: 16.7{\%} of patients who had received Botox, and in 19.7{\%} who had received Dysport (P > 0.05). The most common side effects were palpebral ptosis and lacrimation; ptosis and lagophtalmos was more common in Dysport treatments (P <0.005). Conclusions: Both brands are effective and safe in treating HFS; efficacy is long-lasting. The differences in outcome and side effects confirm that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.",
keywords = "Botox, Botulinum neurotoxin, Dysport, Hemifacial spasm, Treatment",
author = "Bentivoglio, {A. R.} and A. Fasano and T. Ialongo and F. Soleti and {Lo Fermo}, S. and A. Albanese",
year = "2009",
month = "3",
doi = "10.1111/j.1468-1331.2008.02507.x",
language = "English",
volume = "16",
pages = "392--398",
journal = "European Journal of Neurology",
issn = "1351-5101",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "3",

}

TY - JOUR

T1 - Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm

AU - Bentivoglio, A. R.

AU - Fasano, A.

AU - Ialongo, T.

AU - Soleti, F.

AU - Lo Fermo, S.

AU - Albanese, A.

PY - 2009/3

Y1 - 2009/3

N2 - Background and purpose: To review the clinical characteristics and the long-term outcome of patients with hemifacial spasm (HFS) who received botulinum neurotoxin (BoNT) over the past 10 years. Results: A total of 108 patients received 665 treatments. Mean latency of clinical effect was 5.4 ± 5.3 days for Botox and 4.9 ± 4.6 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher after the injection of Dysport than Botox: 105.9 ± 54.2 and 85.4 ± 41.6 days respectively (P <0.01). The percentage of treatment failures was 6.5% for Botox and 4.6% for Dysport (P > 0.05). The doses of Botox significantly increased over time (β = 0.35, P <0. 001) whilst Dysport dose remained unchanged (β = 0.16, n.s.). The duration of clinical benefit slightly increased with Botox (β = 0.12; P <0.01), but remained constant for Dysport. Side effects occurred in 17.4% of treatments: 16.7% of patients who had received Botox, and in 19.7% who had received Dysport (P > 0.05). The most common side effects were palpebral ptosis and lacrimation; ptosis and lagophtalmos was more common in Dysport treatments (P <0.005). Conclusions: Both brands are effective and safe in treating HFS; efficacy is long-lasting. The differences in outcome and side effects confirm that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.

AB - Background and purpose: To review the clinical characteristics and the long-term outcome of patients with hemifacial spasm (HFS) who received botulinum neurotoxin (BoNT) over the past 10 years. Results: A total of 108 patients received 665 treatments. Mean latency of clinical effect was 5.4 ± 5.3 days for Botox and 4.9 ± 4.6 days for Dysport (P > 0.05). Mean duration of clinical improvement was higher after the injection of Dysport than Botox: 105.9 ± 54.2 and 85.4 ± 41.6 days respectively (P <0.01). The percentage of treatment failures was 6.5% for Botox and 4.6% for Dysport (P > 0.05). The doses of Botox significantly increased over time (β = 0.35, P <0. 001) whilst Dysport dose remained unchanged (β = 0.16, n.s.). The duration of clinical benefit slightly increased with Botox (β = 0.12; P <0.01), but remained constant for Dysport. Side effects occurred in 17.4% of treatments: 16.7% of patients who had received Botox, and in 19.7% who had received Dysport (P > 0.05). The most common side effects were palpebral ptosis and lacrimation; ptosis and lagophtalmos was more common in Dysport treatments (P <0.005). Conclusions: Both brands are effective and safe in treating HFS; efficacy is long-lasting. The differences in outcome and side effects confirm that, albeit the active drug is the same, Botox and Dysport should be considered as two different drugs.

KW - Botox

KW - Botulinum neurotoxin

KW - Dysport

KW - Hemifacial spasm

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=60049096833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=60049096833&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1331.2008.02507.x

DO - 10.1111/j.1468-1331.2008.02507.x

M3 - Article

C2 - 19364366

AN - SCOPUS:60049096833

VL - 16

SP - 392

EP - 398

JO - European Journal of Neurology

JF - European Journal of Neurology

SN - 1351-5101

IS - 3

ER -